Phathom Pharmaceuticals, Inc. (PHAT)

NASDAQ: PHAT · IEX Real-Time Price · USD
11.97
-0.03 (-0.25%)
Feb 3, 2023, 4:00 PM EST - Market closed
-0.25%
Market Cap 498.20M
Revenue (ttm) n/a
Net Income (ttm) -178.50M
Shares Out 41.62M
EPS (ttm) -4.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 225,057
Open 11.73
Previous Close 12.00
Day's Range 11.61 - 12.02
52-Week Range 6.10 - 19.95
Beta 0.29
Analysts Buy
Price Target 22.95 (+91.73%)
Earnings Date Mar 7, 2023

About PHAT

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2019
Employees 77
Stock Exchange NASDAQ
Ticker Symbol PHAT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for PHAT stock is "Buy." The 12-month stock price forecast is $22.95, which is an increase of 91.73% from the latest price.

Price Target
$22.95
(91.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phathom Pharmaceuticals, Inc. - PHAT

New York, New York--(Newsfile Corp. - February 2, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. ("Phathom" or the "Company") (NASDAQ: PHAT). Suc...

2 days ago - Newsfile Corp

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT

NEW YORK , Jan. 31, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmac...

5 days ago - PRNewsWire

ROSEN, Leading Investor Counsel, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT

New York, New York--(Newsfile Corp. - January 27, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders o...

1 week ago - Newsfile Corp

PHAT SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT

NEW YORK , Jan. 23, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharma...

1 week ago - PRNewsWire

PHAT EQUITY ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT

New York, New York--(Newsfile Corp. - January 16, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders o...

2 weeks ago - Newsfile Corp

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - January 12, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of P...

3 weeks ago - Newsfile Corp

PHAT INVESTOR ALERT: ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT

NEW YORK , Jan. 12, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmac...

3 weeks ago - PRNewsWire

PHAT Equity Alert: ROSEN, A Leading Law Firm, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT

New York, New York--(Newsfile Corp. - January 10, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders o...

3 weeks ago - Newsfile Corp

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

FLORHAM PARK, N.J., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

3 weeks ago - GlobeNewsWire

Phathom (PHAT) Down on Regulatory Update on Vonoprazan NDA

Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for treating erosive esophagitis.

1 month ago - Zacks Investment Research

Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis

FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

1 month ago - GlobeNewsWire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - PHAT

NEW YORK , Dec. 2, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Phathom Pharmaceutical...

2 months ago - PRNewsWire

PHAT NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT

NEW YORK , Nov. 22, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmac...

2 months ago - PRNewsWire

Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates

FLORHAM PARK, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

3 months ago - GlobeNewsWire

Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences

FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

3 months ago - GlobeNewsWire

PHAT LOSS ALERT: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT

NEW YORK , Nov. 1, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Phathom Pharmaceutical...

3 months ago - PRNewsWire

Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement

FLORHAM PARK, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

3 months ago - GlobeNewsWire

Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)

FLORHAM PARK, N.J., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

3 months ago - GlobeNewsWire

Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

FLORHAM PARK, N.J., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint...

3 months ago - GlobeNewsWire

Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

FLORHAM PARK, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin...

5 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Phathom Pharmaceuticals, Inc. - PHAT

New York, New York--(Newsfile Corp. - August 12, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. ("Phathom" or the "Company") (NASDAQ: PHAT). Such...

6 months ago - Newsfile Corp

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT

NEW YORK , Aug. 11, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Phathom Pharmaceutica...

6 months ago - PRNewsWire

ROSEN, Global Investor Counsel, Encourages Phathom Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Inquire About Securities Class Action Investigation - PHAT

New York, New York--(Newsfile Corp. - August 9, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Phatho...

6 months ago - Newsfile Corp

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pha...

6 months ago - Newsfile Corp

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 5, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pha...

6 months ago - Newsfile Corp